On September 12, 2022 Synthekine Inc., an engineered cytokine therapeutics company, reported that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry (Press release, Synthekine, SEP 12, 2022, View Source [SID1234619451]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are honored to be recognized as a Fierce 15 company, reflecting the potential of our distinct cytokine engineering platforms to harness the power of cytokine therapeutics," said Debanjan Ray, Chief Executive Officer of Synthekine. "I am particularly proud of the substantial progress our talented and dedicated team has made in the three years since Synthekine was founded. Looking ahead, we are eager to build upon the momentum of our maturing pipeline and continue to advance novel cytokine science for the benefit of patients with debilitating cancers and inflammatory diseases."
Synthekine recently moved STK-012, its IL-2 partial agonist, into clinical investigation and secured its first pharmaceutical partnership on its novel surrogate cytokine agonist platform. The company anticipates entering the clinic later this year with its second program, STK-009 + SYNCAR-001, to address key limitations of current CD19 CAR-T cell therapies.
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 20th annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.